Key Developments For Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. (JAZZ.O) (Consolidated Issue listed on NASDAQ Global Market)
Jazz Pharmaceuticals, Inc. Raises FY 2009 Revenue Guidance
Jazz Pharmaceuticals, Inc. increased fiscal 2009 guidance for total revenues to be $122 - $127 million from prior range of $112 - $122 million. According to Reuters Estimates, analysts on an average were expecting the Company to report revenue of $119 million for the same period.
Jazz Pharmaceuticals, Inc. Completes Two Phase III Pivotal Clinical Trials of JZP-6
Jazz Pharmaceuticals, Inc. announced that it has completed two Phase III pivotal clinical trials of JZP-6, with positive results in both studies. Jazz Pharmaceuticals is working to submit a New Drug Application for sodium oxybate for the treatment of fibromyalgia to the U.S. Food and Drug Administration by the end of 2009.
FAES Farma, S.A. Terminates Flufenoxina License Agreement With Jazz Pharmaceuticals Inc.
FAES Farma S.A. announced that it has agreed together with Jazz Pharmaceuticals Inc. to terminate the license agreement of Flufenoxina, antidepressant agreed in 2007, so that FAES Farma SA can develop the project of the molecule Flufenoxina in the new indication for Alzheimer. The advanced research of FAES Farma S.A. on the nervous system has revealed that analogues of Flufenoxina show activity in the in vitro test for Alzheimer. This recent finding and the agreement allows Faes Farma SA to restore the rights of intellectual property of the molecule, and move forward with the investigation in this indication without limitation patent.
Jazz Pharmaceuticals, Inc. Issues FY 2009 Revenue Guidance Above Analysts' Estimates
Jazz Pharmaceuticals, Inc. announced that for fiscal 2009, it expects total revenues to be $112-$122 million. According to Reuters Estimates, analysts were expecting the Company to report revenue of $103 million for fiscal 2009.
Jazz Pharmaceuticals, Inc. Completes $7 Million Private Placement
Jazz Pharmaceuticals, Inc. announced the signing and closing of a private placement of an aggregate of 1,895,734 units, comprised of an aggregate of 1,895,734 shares of common stock and warrants to purchase up to 947,867 additional shares of common stock for aggregate gross proceeds of approximately $7 million. The per unit purchase price for a share of common stock and a warrant to purchase 0.50 of a share of common stock was $3.6925. The warrants have an exercise price of $4.00 per share and are exercisable for seven years. The gross proceeds of the private placement were $7.0 million, and the Company intends to use the proceeds for general corporate purposes. The units were purchased by funds affiliated with Longitude Capital. In connection with the transaction, Patrick Enright, a Managing Director of Longitude Capital, joined Jazz Pharmaceuticals' Board of Directors.
